Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies could significantly improve outcomes in patients with high-risk, relapsed chronic lymphocytic leukemia (CLL), according to a new report. The authors of the report, which is b... [3878 chars].. reed more
